DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)

Not Applicable

Completed

Conditions: Fitness Trackers
Breast Cancer Survivor
Breast Cancer

Interventions: Other: Move Together app/Garmin Activity Tracker

First Posted Date: 2021-08-18

Last Posted Date: 2023-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT05011279

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Massachusetts Boston, Boston, Massachusetts, United States

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Not Applicable

Recruiting

Conditions: Ovarian Cancer Stage IV
Ovarian Cancer Stage III
Ovarian Cancer
Ovarian Cancer Stage 3
Ovarian Carcinoma
Endometrial Cancer
Endometrial Cancer Stage

Interventions: Other: Attention Control
Other: Exercise

First Posted Date: 2021-08-09

Last Posted Date: 2024-02-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04997096

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Scalp Cooling in MBC

Phase 2

Recruiting

Conditions: Chemotherapy-induced Alopecia
Metastatic Breast Cancer

Interventions: Device: Paxman Scalp Cooling System
Drug: Trastuzumab deruxtecan
Drug: Eribulin
Drug: Sacituzumab govitecan

First Posted Date: 2021-08-03

Last Posted Date: 2024-11-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 120

Registration Number: NCT04986579

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Protocol for Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens from Children and Young Adults with Hematologic Malignancy

Recruiting

Conditions: Myelodysplastic Syndromes
Leukemia
Myeloproliferative Syndrome

Interventions: Genetic: Genomic profiling

First Posted Date: 2021-07-20

Last Posted Date: 2024-11-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 300

Registration Number: NCT04968834

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

and more 5 locations

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Active, not recruiting

Conditions: HPV
Oropharyngeal Squamous Cell Carcinoma

Interventions: Other: Screening

First Posted Date: 2021-07-16

Last Posted Date: 2024-07-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 150

Registration Number: NCT04965792

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Axillary Lymph Node Tattoo Marking Study

Not Applicable

Terminated

Conditions: Lymph Node Metastases
Breast Cancer

Interventions: Procedure: SpotTM Tattoo Ink

First Posted Date: 2021-07-01

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT04947917

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma
Relapsed Hodgkin's Disease, Adult
Refractory Hodgkin Lymphoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2021-06-24

Last Posted Date: 2024-03-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT04938232

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

and more 1 locations

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

Not Applicable

Completed

Conditions: Prostate Cancer
Patient Preference
Patient Satisfaction
Breast Cancer
Patient Engagement

Interventions: Behavioral: FOLLOW UP VISIT-TELEMEDICINE
Behavioral: FOLLOW UP VISIT-FACE TO FACE

First Posted Date: 2021-06-23

Last Posted Date: 2022-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04936243

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Phase 1

Recruiting

Conditions: Metastatic Melanoma
Melanoma

Interventions: Drug: CDX-301
Biological: NEOVAX
Drug: Nivolumab
Drug: Pembrolizumab

First Posted Date: 2021-06-18

Last Posted Date: 2024-03-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04930783

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Not Applicable

Recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy
Nerve Pain
Neuropathy
Neuropathy, Painful
Pain
CIPN - Chemotherapy-Induced Peripheral Neuropathy

Interventions: Other: Sham Acupuncture
Other: Electroacupuncture

First Posted Date: 2021-06-08

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 250

Registration Number: NCT04917796

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy